P1, N=57, Terminated, Lyell Immunopharma, Inc. | N=100 --> 57 | Trial completion date: Dec 2026 --> Nov 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2025 --> Nov 2024; Pipeline Reprioritization

P1, N=3, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial primary completion date: Jan 2026 --> Mar 2025

P1, N=3, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Recruiting --> Active, not recruiting | N=88 --> 3

P1, N=100, Active, not recruiting, Lyell Immunopharma, Inc. | Recruiting --> Active, not recruiting

P1/2, N=9, Terminated, Oncternal Therapeutics, Inc | N=57 --> 9 | Trial completion date: Dec 2037 --> Sep 2024 | Recruiting --> Terminated | Trial primary completion date: Dec 2026 --> Sep 2024; Based on the available clinical data and capital requirements for continued development, the Company has decided to terminate this study.

P1, N=100, Recruiting, Lyell Immunopharma, Inc. | N=54 --> 100 | Trial completion date: Sep 2026 --> Dec 2026 | Trial primary completion date: Mar 2025 --> Dec 2025

P1, N=54, Recruiting, Lyell Immunopharma, Inc.

Zilovertamab vedotin showed preliminary evidence of efficacy and no evidence of on-target off-tumor toxicity in patients with advanced B cell malignancies (Wang 2022)...Subjects will receive a conditioning regimen of intravenous (IV) cyclophosphamide and fludarabine, followed by ONCT-808 IV infusion...The trial is currently active and patients have been treated in the phase 1 dose escalation. Clinical Trial Identifier: NCT05588440

After successful LYL797 manufacturing, pts receive fludarabine and cyclophosphamide followed by a single infusion of LYL797 at the protocol-assigned dose level. Study objectives include assessment of safety and tolerability (primary), as well as anti-tumor activity and pharmacokinetics (secondary) of LYL797. Additional exploratory objectives include evaluation of the effects of Lyell’s genetic and epigenetic reprogramming technologies on T-cell phenotype and activity, as well as evaluation of the relationship between ROR1 expression and LYL797 activity.

1x106 CAR T cells (figure 2). Conclusions These data suggest that LYL119, which combines c-Jun overexpression, NR4A3 KO, Epi-R protocol, and Stim-R technology, can limit exhaustion, maintain stem-like features, and has potential to provide effective and durable CAR T-cell antitumor activity in patients with ROR1+ solid tumors.

Oncternal’s ONCT-808 autologous CAR T cells are genetically modified via ex vivo transduction with a self-inactivating lentivirus vector to express a ROR1-directed CAR containing single chain variable fragment derived from Oncternal’s clinical stage anti-ROR1 zilovertamab. In cancer therapy efficacy studies using CDX models, treatment with ONCT-808 cells resulted in complete tumor remission in ROR1 Jeko-1 cell-derived CDX mice, and controlled tumor growth in Raji cell-derived CDX mice, reflecting the specificity of the ONCT-808 cells to the ROR1 target. Conclusions ONCT-808 demonstrated high efficacy in inducing ROR1 specific cancer cell death in both in vivo and in vitro studies, suggesting its potential in treating human cancer patients.

P1, N=5, Terminated, Bristol-Myers Squibb | N=65 --> 5 | Trial completion date: Mar 2025 --> May 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Mar 2025 --> May 2023; Business objectives have changed.